Seroatlas · Human Serome Atlas

ELAC2

Zinc phosphodiesterase ELAC protein 2

Also known as: FLJ10530, HPC2, RNZ2_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9BQ52
Gene
ELAC2
Ensembl
ENSG00000006744
Chromosome
17
Canonical length
826 aa
Protein class
Disease related genes, Enzymes, Human disease related genes, Plasma proteins, Potential drug targets, Predicted intracellular proteins
Subcellular location
Nucleoplasm
Quaternary structure
Homodimer

OverviewNCBI Gene

The protein encoded by this gene has a C-terminal domain with tRNA 3′ processing endoribonuclease activity, which catalyzes the removal of the 3' trailer from precursor tRNAs. The protein also interacts with activated Smad family member 2 (Smad2) and its nuclear partner forkhead box H1 (also known as FAST-1), and reduced expression can suppress transforming growth factor-beta induced growth arrest. Mutations in this gene result in an increased risk of prostate cancer. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Sep 2009]

Canonical amino-acid sequenceUniProt

826 residues, UniProt reviewed canonical sequence.

>Q9BQ52|ELAC2
     1  MWALCSLLRS AAGRTMSQGR TISQAPARRE RPRKDPLRHL RTREKRGPSG CSGGPNTVYL
    61  QVVAAGSRDS GAALYVFSEF NRYLFNCGEG VQRLMQEHKL KVARLDNIFL TRMHWSNVGG
   121  LSGMILTLKE TGLPKCVLSG PPQLEKYLEA IKIFSGPLKG IELAVRPHSA PEYEDETMTV
   181  YQIPIHSEQR RGKHQPWQSP ERPLSRLSPE RSSDSESNEN EPHLPHGVSQ RRGVRDSSLV
   241  VAFICKLHLK RGNFLVLKAK EMGLPVGTAA IAPIIAAVKD GKSITHEGRE ILAEELCTPP
   301  DPGAAFVVVE CPDESFIQPI CENATFQRYQ GKADAPVALV VHMAPASVLV DSRYQQWMER
   361  FGPDTQHLVL NENCASVHNL RSHKIQTQLN LIHPDIFPLL TSFRCKKEGP TLSVPMVQGE
   421  CLLKYQLRPR REWQRDAIIT CNPEEFIVEA LQLPNFQQSV QEYRRSAQDG PAPAEKRSQY
   481  PEIIFLGTGS AIPMKIRNVS ATLVNISPDT SLLLDCGEGT FGQLCRHYGD QVDRVLGTLA
   541  AVFVSHLHAD HHTGLPSILL QRERALASLG KPLHPLLVVA PNQLKAWLQQ YHNQCQEVLH
   601  HISMIPAKCL QEGAEISSPA VERLISSLLR TCDLEEFQTC LVRHCKHAFG CALVHTSGWK
   661  VVYSGDTMPC EALVRMGKDA TLLIHEATLE DGLEEEAVEK THSTTSQAIS VGMRMNAEFI
   721  MLNHFSQRYA KVPLFSPNFS EKVGVAFDHM KVCFGDFPTM PKLIPPLKAL FAGDIEEMEE
   781  RREKRELRQV RAALLSRELA GGLEDGEPQQ KRAHTEEPQA KKVRAQ

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against ELAC2 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Intracellular
Secreted
No
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.29
Highest tissue expression
56 nTPM

Expression across tissuesHPA

Tissue

  • skeletal muscle: 56 nTPM
  • heart muscle: 36 nTPM
  • tonsil: 35 nTPM
  • tongue: 33 nTPM
  • adrenal gland: 33 nTPM
  • parathyroid gland: 32 nTPM

Single-cell type

  • cytotrophoblasts: 76 nCPM
  • epicardial cells: 66 nCPM
  • migrating cytotrophoblasts: 56 nCPM
  • esophageal basal cells: 50 nCPM
  • esophageal suprabasal cells: 44 nCPM
  • extravillous trophoblasts: 37 nCPM

Immune cell

  • NK-cell: 54 nTPM
  • T-reg: 54 nTPM
  • myeloid DC: 49 nTPM
  • non-classical monocyte: 47 nTPM
  • total PBMC: 46 nTPM
  • MAIT T-cell: 44 nTPM

Brain region

  • white matter: 57 nTPM
  • choroid plexus: 50 nTPM
  • spinal cord: 48 nTPM
  • medulla oblongata: 47 nTPM
  • pons: 44 nTPM
  • hypothalamus: 44 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about ELAC2.

Disease | AllUniProt

Conditions ELAC2 is implicated in, by any mechanism.

Disease | GeneticClinVar

82 pathogenic / likely-pathogenic of 1,270 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Disease | ImmuneIEDB

Conditions an epitope on ELAC2 was assayed in.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
1.05
gnomAD pLI
0
gnomAD missense Z
-0.41
DepMap mean gene effect
-0.92
DepMap dependency class
common

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of ELAC2 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads ELAC2 as an antibody target. Whether an autoantibody or antibody against ELAC2 could matter depends on whether native ELAC2 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

ELAC2 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label ELAC2 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/ELAC2. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

Loading the interactive Seroatlas protein explorer...